Lineage Cell announces 36-month results for Phase 1/2a trial of RG6501

Lineage Cell Therapeutics (LCTX) announced that 36-month results from patients enrolled in a Phase 1/2a clinical study of RG6501 in patients with geographic atrophy secondary to age-related macular degeneration, will be presented at Clinical Trials at the Summit, CTS, 2025. CTS will be held June 20 – 21, 2025, and brings together a diverse group of experts from around the world to discuss ongoing clinical trials and the latest data, all with the goal of achieving advances in vitreoretinal care. The presentation, “OpRegen Retinal Pigment Epithelium Cell Therapy for Patients with Geographic Atrophy: Month 36 Results from the Phase 1/2a Trial,” will be presented by Christopher D. Riemann, M.D., Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute and University of Cincinnati School of Medicine, on behalf of Roche and Genentech, a member of the Roche Group.